Drug General Information (ID: DDICVBDT6A)
  Drug Name Streptokinase Drug Info Tranexamic acid Drug Info
  Drug Type Protein/peptide Small molecule
  Therapeutic Class Thrombolytics Antifibrinolytic Agents
  Structure

 Mechanism of Streptokinase-Tranexamic acid Interaction (Severity Level: Moderate)
     Antagonize the effect of antithrombotic agents Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Streptokinase Tranexamic acid
      Mechanism Thrombolytic agent Thrombogenic effects
      Key Mechanism Factor 1
Factor Name Antithrombotic agents
Factor Description The beneficial effects of antithrombotic agents are reduced, leading to an increased risk of thromboembolism, stroke and/or myocardial infarction.
      Mechanism Description
  • Antagonize the effect of Streptokinase when combined with Tranexamic acid 

Recommended Action
      Management No specific intervention is warranted, but clinicians should be alert to the potential for diminished therapeutic efficacy if a tissue plasminogen activator is administered to a patient who has been treated with an antifibrinolytic agent, and vice versa.

References
1 Product Information. LYSTEDA (tranexamic acid). Xanodyne Pharmaceuticals Inc, Newport, KY.
2 Product Information. Cyklokapron (tranexamic acid). Pharmacia and Upjohn, Kalamazoo, MI.
3 Product Information. Trasylol (aprotinin). Bayer, West Haven, CT.